Prolight Diagnostics advanced its Psyros POC system, secured SEK 12.6 million via warrant exercise, and maintained a strong cash position despite ongoing losses as it prepares for clinical validation in 2025. POC and cardiac biomarker markets show robust growth potential.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.